Connect
Discussion
Comment receiving replies
Replies to "Here are the links to the articles @pjsatz references: - ARX517/JNJ-95298177 as Monotherapy or Combination Therapy..."
Prostate Cancer | Last Active: May 4 6:37pm | Replies (3)
Comment receiving replies
Here are the links to the articles @pjsatz references:
- ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer https://clinicaltrials.ucsf.edu/trial/NCT04662580
- Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/39172730/
Replies to "Here are the links to the articles @pjsatz references: - ARX517/JNJ-95298177 as Monotherapy or Combination Therapy..."
Thank you.. There are also articles, results from a phase 1/2 trial.
Search for
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
Thank you
Phil
Connect
Thank you, Colleen. That paper offers much hope to those who become castrate resistant. And it delivers its payload without radiation, like Pluvicto.
Not sure if it would be used in all cases or just soft tissue but it is a big leap forward in targeting the actual cancer and not healthy cells at the same time. Many thanks!
Phil